AGENUS INC.

AGEN · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.

ESG Overview

Overall: BB (Medium)

E: BS: BG: BB

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $3.41 +0.26 (+8.25%)

Market Cap$107M

P/E Ratio—

EPS$—

52W High$7.34

52W Low$1.38

Beta1.64

Data from Finnhub · Updated Mar 10, 2026